Here are relevant reports on : parkinsons-disease-market
-
Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria - Global Forecast to 2028
The global cardiac marker testing market, valued at US$4.1 billion in 2022, stood at US$4.4 billion in 2023 and is projected to advance at a resilient CAGR of 9.4% from 2023 to 2028, culminating in a forecasted valuation of US$6.9 billion by the end of the period. Increase in chronic heart conditions and aging population, increasing research & funding initiatives from organizations and worldwide rise in prevalence of cardiovascular diseases are a few drivers that collectively contribute to the growth of this market.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Injectable Pharma Packaging Market by Type (Prefilled Syringes, Vials, Ampoules, Cartridges), Packaging Type (Primary, Secondary), Application (Chronic Disease Management, Vaccines, Biologics, Insulin, Oncology), and Region-Global Forecast to 2030
Injectable Pharma Packaging Market is projected to reach USD 98.8 billion by 2030 from USD 44.8 billion in 2025, at a CAGR of 17.5% during the forecast period. The key players in the injectable pharma packaging market include Schott AG (Germany), Gerresheimer AG (Germany), West Pharmaceutical Services (US), Stevanato Group (Italy), BD (Becton, Dickinson and Company) (US), SGD Pharma (France), Nipro Corporation (Japan), AptarGroup (US), Catalent, Inc. (US), and Datwyler Group (Switzerland).
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030
The global genomic biomarkers market, valued at US$26.78 billion in 2024, stood at US$29.00 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2024 to 2030, culminating in a forecasted valuation of US$50.31 billion by the end of the period. Genomic biomarkers are measurable features of DNA and RNA used to aid disease diagnosis, characterize disease states, and guide therapeutic decision-making.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031
The global human microbiome market, valued at USD 0.91 billion in 2024, stood at USD 1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of USD 7.09 billion by the end of the period. North American market held the largest share during the forecast period due to the rising investments by governments and industries, and presence of a strong human microbiome ecosystem supporting innovation in this field.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The North America vaccines market, valued at US$25.95 billion in 2024, stood at US$25.29 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2025 to 2030, culminating in a forecasted valuation of US$35.68 billion by the end of the period. The vaccines market is growing rapidly, driven by swift global vaccine development and commercialization, higher rates of infectious diseases necessitating preventive vaccines, expanded immunization initiatives, innovations in vaccine technology, and increased government funding and investments for novel vaccines against diverse diseases.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029
The global biosimulation market, valued at US$3.64 billion in 2023, stood at US$4.24 billion in 2024 and is projected to advance at a resilient CAGR of 16.7% from 2024 to 2029, culminating in a forecasted valuation of US$9.18 billion by the end of the period. The major factors driving the growth of this market include the high rate of clinical trial failures, the increasing necessity to predict drug pharmacokinetics and pharmacodynamics, and the importance of toxicity management.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Digital Pathology Market by Product (Scanner, Software, Storage System), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma & Biotech, Academia, Hospitals) - Global Forecast to 2030
Global digital pathology market valued at $1.30B in 2024, reached $1.46B in 2025, and is projected to grow at a robust 13.5% CAGR, hitting $2.75B by 2030. The key driver of this growth is the mounting need for telepathology to enable pathologists to remotely view slides and interact live over distances. The other factor is integrating artificial intelligence (AI) in digital pathology systems, boosting diagnostics through automated image analysis and predictive analytics.
- Published: May 2025
- Price: $ 4950
- TOC Available:
-
Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030
The global veterinary biologics market, valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention.
- Published: October 2025
- Price: $ 4950
- TOC Available:
-
Asia Pacific Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Diseases), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Asia Pacific Human Microbiome Market, valued at US$0.19 billion in 2024, stood at US$0.26 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. Market growth is driven by an increasing focus on preventive and personalized health, rising adoption of microbiome-based diagnostics and therapeutic solutions, and rapid advances in next-generation sequencing, AI-enabled microbiome analytics, and regional bioinformatics capabilities.
- Published: May 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
